Regencell Bioscience (NASDAQ:RGC) Shares Down 18.4% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price was down 18.4% during mid-day trading on Tuesday . The stock traded as low as $35.75 and last traded at $35.99. Approximately 379,673 shares were traded during trading, a decline of 76% from the average daily volume of 1,569,285 shares. The stock had previously closed at $44.11.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Regencell Bioscience Trading Down 22.1%

The stock has a 50-day moving average of $19.08 and a 200 day moving average of $16.56.

Hedge Funds Weigh In On Regencell Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in RGC. Squarepoint Ops LLC bought a new stake in Regencell Bioscience in the second quarter worth about $1,701,000. Geode Capital Management LLC increased its stake in shares of Regencell Bioscience by 5,637.5% during the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock worth $6,664,000 after purchasing an additional 384,250 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Regencell Bioscience in the 2nd quarter worth approximately $222,000. XTX Topco Ltd bought a new position in Regencell Bioscience during the third quarter valued at $598,000. Finally, BNP Paribas Financial Markets purchased a new stake in Regencell Bioscience in the second quarter worth $768,000. 0.13% of the stock is owned by hedge funds and other institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.